CY1111962T1 - Πυριμιδινυλ-πιπεραζινες χρησιμες ως συνδετηρες υποδοχεα d3/d2 ντοπαμινης - Google Patents

Πυριμιδινυλ-πιπεραζινες χρησιμες ως συνδετηρες υποδοχεα d3/d2 ντοπαμινης

Info

Publication number
CY1111962T1
CY1111962T1 CY20111101000T CY111101000T CY1111962T1 CY 1111962 T1 CY1111962 T1 CY 1111962T1 CY 20111101000 T CY20111101000 T CY 20111101000T CY 111101000 T CY111101000 T CY 111101000T CY 1111962 T1 CY1111962 T1 CY 1111962T1
Authority
CY
Cyprus
Prior art keywords
pyrimidinyl
dopamine receptors
piperazines useful
relates
piperazines
Prior art date
Application number
CY20111101000T
Other languages
English (en)
Inventor
Szalai Gizella Bartáné
Csongor Éva Ágainé
György Domány
István Gyertyán
Béla Kiss
Judit Laszy
Katalin Sághy
Éva Schmidt
Sándor Farkas
Zsolt Komlódi
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of CY1111962T1 publication Critical patent/CY1111962T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέους συνδετήρες D3 και D2 ντοπαμίνης του τύπου (Ι): όπου τα R1, R2 και Q είναι όπως περιγράφεται στον παρόν ή/και γεωμετρικά ισομερή ή/και στερεοϊσομερή ή/και διαστερεομερή ή/και άλατα ή/και υδρίτες ή/και διαλυτώματα ή/και πολύμορφα αυτών. Η εφεύρεση επίσης αφορά μέθοδο παρασκευής αυτών, συνθέσεις που τα περιέχουν και χρήση αυτών στην θεραπεία ή/και πρόληψη καταστάσεων που απαιτούν ρύθμιση των υποδοχέων ντοπαμίνης.
CY20111101000T 2007-04-11 2011-10-21 Πυριμιδινυλ-πιπεραζινες χρησιμες ως συνδετηρες υποδοχεα d3/d2 ντοπαμινης CY1111962T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
EP08737283A EP2132185B1 (en) 2007-04-11 2008-04-10 Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands

Publications (1)

Publication Number Publication Date
CY1111962T1 true CY1111962T1 (el) 2015-11-04

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101000T CY1111962T1 (el) 2007-04-11 2011-10-21 Πυριμιδινυλ-πιπεραζινες χρησιμες ως συνδετηρες υποδοχεα d3/d2 ντοπαμινης

Country Status (36)

Country Link
EP (1) EP2132185B1 (el)
JP (1) JP4580464B2 (el)
KR (1) KR101540821B1 (el)
CN (1) CN101652351B (el)
AP (1) AP2460A (el)
AT (1) ATE518843T1 (el)
AU (1) AU2008237696B2 (el)
BR (1) BRPI0809641A2 (el)
CA (1) CA2682817C (el)
CO (1) CO6241116A2 (el)
CR (1) CR11071A (el)
CU (1) CU23853B1 (el)
CY (1) CY1111962T1 (el)
DK (1) DK2132185T3 (el)
EA (1) EA016174B1 (el)
EC (1) ECSP099702A (el)
ES (1) ES2370748T3 (el)
GE (1) GEP20115272B (el)
HK (1) HK1134491A1 (el)
HR (1) HRP20110785T8 (el)
HU (1) HUP0700269A2 (el)
IL (1) IL200801A0 (el)
MA (1) MA31359B1 (el)
MX (1) MX2009010896A (el)
MY (1) MY148384A (el)
NI (1) NI200900179A (el)
NZ (1) NZ579754A (el)
PL (1) PL2132185T3 (el)
PT (1) PT2132185E (el)
RS (1) RS51979B (el)
SI (1) SI2132185T1 (el)
TN (1) TN2009000386A1 (el)
TW (1) TWI445534B (el)
UA (1) UA103748C2 (el)
WO (1) WO2008125891A2 (el)
ZA (1) ZA200906543B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
LT2582701T (lt) 2010-06-18 2017-03-27 Altos Therapeutics, LLC D2 antagonistai, sintezės būdai ir panaudojimo būdai
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN111801330B (zh) 2018-01-26 2024-04-05 盐野义制药株式会社 具有多巴胺d3受体拮抗作用的稠环化合物
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Also Published As

Publication number Publication date
JP4580464B2 (ja) 2010-11-10
BRPI0809641A2 (pt) 2014-11-11
WO2008125891A2 (en) 2008-10-23
HRP20110785T8 (en) 2012-04-30
PT2132185E (pt) 2011-11-21
CN101652351B (zh) 2012-07-04
EA016174B1 (ru) 2012-02-28
SI2132185T1 (sl) 2011-11-30
HK1134491A1 (en) 2010-04-30
CU23853B1 (es) 2012-10-15
NI200900179A (es) 2010-06-30
MY148384A (en) 2013-04-15
IL200801A0 (en) 2010-05-17
UA103748C2 (uk) 2013-11-25
KR20100082713A (ko) 2010-07-19
CA2682817C (en) 2015-11-24
HUP0700269A2 (en) 2009-04-28
CN101652351A (zh) 2010-02-17
MX2009010896A (es) 2009-12-14
AP2009004970A0 (en) 2009-10-31
CO6241116A2 (es) 2011-01-20
MA31359B1 (fr) 2010-05-03
ZA200906543B (en) 2010-06-30
NZ579754A (en) 2011-11-25
RS51979B (en) 2012-02-29
TN2009000386A1 (en) 2010-12-31
JP2010523642A (ja) 2010-07-15
HU0700269D0 (en) 2007-05-29
GEP20115272B (en) 2011-08-25
TWI445534B (zh) 2014-07-21
AP2460A (en) 2012-09-13
AU2008237696A1 (en) 2008-10-23
WO2008125891A3 (en) 2009-01-08
AU2008237696B2 (en) 2013-03-14
ATE518843T1 (de) 2011-08-15
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
CU20090161A7 (es) 2011-09-21
TW201002328A (en) 2010-01-16
KR101540821B1 (ko) 2015-07-30
ECSP099702A (es) 2009-11-30
ES2370748T3 (es) 2011-12-22
CA2682817A1 (en) 2008-10-23
EP2132185A2 (en) 2009-12-16
PL2132185T3 (pl) 2011-12-30
DK2132185T3 (da) 2011-10-03
EP2132185B1 (en) 2011-08-03
HRP20110785T1 (hr) 2011-11-30

Similar Documents

Publication Publication Date Title
CY1111962T1 (el) Πυριμιδινυλ-πιπεραζινες χρησιμες ως συνδετηρες υποδοχεα d3/d2 ντοπαμινης
CY1122944T1 (el) Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων
HRP20120129T1 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
EA201000050A1 (ru) Замещенные бициклолактамные соединения
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
MY150062A (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
CY1116721T1 (el) Νεες ενωσεις ως προσδεματα υποδοχεων ισταμινης η3
MX2009008028A (es) Agentes antiparasitarios.
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
EA201270556A1 (ru) Конденсированные тиазоло и оксазолопиримидиноны
EA201290610A1 (ru) Сульфоновые соединения в качестве лигандов 5-htрецептора
EA201290344A1 (ru) БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ЛИГАНДОВ αβНИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2010007929A (es) Imidazolinilmetil aril sulfonamidas novedosas.
MY152069A (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation threof, and therepeutic use thereof
EA201170461A1 (ru) Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht